Saltar al contenido

Edwards Lifesciences Corp (EW) stock: revenue, earnings & dividend

Edwards Lifesciences Corp (EW, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener EW · NYSE Medizintechnik & Messgeräte US-CA

Key figures

Fiscal year
2025
Revenue
6.07 bn $
Revenue growth
11.6 %
Revenue growth 5y (p.a.)
6.7 %
Net income
1.07 bn $
Net margin
17.7 %
Operating margin
20.8 %
Earnings per share (diluted)
1.83 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
13.7 bn $
Equity
10.3 bn $
Equity ratio
75.5 %
Return on equity
10.4 %
Cash
2.94 bn $
Operating cash flow
1.6 bn $
Free cash flow
1.34 bn $
Shares outstanding
575,000,000

History

Revenue by fiscal year

2016 2.96 bn $
2017 3.44 bn $
2018 3.72 bn $
2019 4.35 bn $
2020 4.39 bn $
2021 5.23 bn $
2022 4.46 bn $
2023 5.01 bn $
2024 5.44 bn $
2025 6.07 bn $

Net income by fiscal year

2021 1.5 bn $
2022 1.52 bn $
2023 1.4 bn $
2024 4.17 bn $
2025 1.07 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20256.07 bn $1.07 bn $1.83 $–1.6 bn $
20245.44 bn $4.17 bn $6.97 $–542 m $
20235.01 bn $1.4 bn $2.30 $–896 m $
20224.46 bn $1.52 bn $2.44 $–1.22 bn $
20215.23 bn $1.5 bn $2.38 $–1.73 bn $
20204.39 bn $–1.30 $–1.05 bn $
20194.35 bn $–1.64 $–1.18 bn $
20183.72 bn $–1.13 $–927 m $
20173.44 bn $–2.70 $–1 bn $
20162.96 bn $–2.61 $–704 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)